Market | Leadsynbio shines at CPHI China 2026 with a diversified biomanufacturing product portfolio

From June 16 to 18, CPHI China 2026 was held at the Shanghai New International Expo Centre. Leadsynbio made a strong impression at Booth No. W4F49, showcasing a range of synthetic biology achievements and its internationally competitive product portfolio, while engaging with industry peers to explore future trends and partnership opportunities.

On-site, Leadsynbio featured its core products including Florfenicol, 25-Hydroxy Vitamin D₃, and NMN, covering both API intermediates and nutritional ingredients. Backed by consistent high quality and reliable supply capabilities, these products have been exported to multiple countries and regions worldwide, earning long-term trust from international customers.

Behind this strong market presence lies Leadsynbio's continued commitment to synthetic biology innovation. Leveraging its self-developed R&D platform, the company has been optimizing production processes while accelerating the development and launch of new product lines — extending the green benefits of biomanufacturing to a broader range of industries. In the first half of this year, the newly launched L-Selenomethionine for animal nutrition quickly gained industry recognition. Looking ahead, a series of carotenoid products including β-Carotene, Astaxanthin, Canthaxanthin, and Zeaxanthin will be rolled out successively, further enriching the product matrix and offering global customers a wider selection of biomanufactured raw materials.

Having exhibited at CPHI China for multiple consecutive years, Leadsynbio remains at the forefront of the biomanufacturing industry. Going forward, the company will accelerate the commercialization of new products, driving high-quality industry development through synthetic biology innovation.